Saltar al contenido
Merck
  • A resorbable antibiotic-eluting polymer composite bone void filler for perioperative infection prevention in a rabbit radial defect model.

A resorbable antibiotic-eluting polymer composite bone void filler for perioperative infection prevention in a rabbit radial defect model.

PloS one (2015-03-31)
Benjamin D Brooks, Kristofer D Sinclair, David W Grainger, Amanda E Brooks
RESUMEN

Nearly 1.3 million total joint replacement procedures are performed in the United States annually, with numbers projected to rise exponentially in the coming decades. Although finite infection rates for these procedures remain consistently low, device-related infections represent a significant cause of implant failure, requiring secondary or revision procedures. Revision procedures manifest several-fold higher infection recurrence rates. Importantly, many revision surgeries, infected or not, require bone void fillers to support the host bone and provide a sufficient tissue bed for new hardware placement. Antibiotic-eluting bone void fillers (ABVF), providing both osteoconductive and antimicrobial properties, represent one approach for reducing rates of orthopedic device-related infections. Using a solvent-free, molten-cast process, a polymer-controlled antibiotic-eluting calcium carbonate hydroxyapatite (HAP) ceramic composite BVF (ABVF) was fabricated, characterized, and evaluated in vivo using a bacterial challenge in a rabbit radial defect window model. ABVF loaded with tobramycin eliminated the infectious burden in rabbits challenged with a clinically relevant strain of Staphylococcus aureus (inoculum as high as 10⁷ CFU). Histological, microbiological, and radiographic methods were used to detail the effects of ABVF on microbial challenge to host bone after 8 weeks in vivo. In contrast to the HAP/BVF controls, which provided no antibiotic protection and required euthanasia 3 weeks post-operatively, tobramycin-releasing ABVF animals showed no signs of infection (clinical, microbiological, or radiographic) when euthanized at the 8-week study endpoint. ABVF sites did exhibit fibrous encapsulation around the implant at 8 weeks. Local antibiotic release from ABVF to orthopedic sites requiring bone void fillers eliminated the periprosthetic bacterial challenge in this 8-week in vivo study, confirming previous in vitro results.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Formaldehído solution, for molecular biology, 36.5-38% in H2O
SAFC
Formaldehído solution, contains 10-15% methanol as stabilizer, 37 wt. % in H2O
Sigma-Aldrich
Metilmetacrilato, contains ≤30 ppm MEHQ as inhibitor, 99%
Sigma-Aldrich
Formaldehído solution, for molecular biology, BioReagent, ≥36.0% in H2O (T)
Sigma-Aldrich
L-Lysine monohydrochloride, from non-animal source, meets EP, JP, USP testing specifications, suitable for cell culture, 98.5-101.0%
Sigma-Aldrich
Formaldehído solution, ACS reagent, 37 wt. % in H2O, contains 10-15% Methanol as stabilizer (to prevent polymerization)
Supelco
Formaldehído solution, stabilized with methanol, ~37 wt. % in H2O, certified reference material
Sigma-Aldrich
Metilmetacrilato, 99%, stabilized
Sigma-Aldrich
Polyethyleneglycol Bisphenol A Epichlorohydrin Copolymer, mol wt 15,000-20,000 Da
Sigma-Aldrich
Formaldehído solution, meets analytical specification of USP, ≥34.5 wt. %
Sigma-Aldrich
L-Lysine monohydrochloride, reagent grade, ≥98% (HPLC)
Sigma-Aldrich
Formaldehído solution, tested according to Ph. Eur.
Sigma-Aldrich
Benzoin methyl ether, 96%
Sigma-Aldrich
Formaldehído solution, SAJ first grade, ≥35.0%, contains methanol as stabilizer
Sigma-Aldrich
Formaldehído solution, 10%
Sigma-Aldrich
Formaldehído solution, JIS special grade, 36.0-38.0%, contains methanol as stabilizer
Sigma-Aldrich
mono-Butyl phthalate, 97.0-103.0% (T)
Sigma-Aldrich
Benzoin methyl ether, 99%
Sigma-Aldrich
Formaldehyde-12C solution, 20% in H2O, 99.9 atom % 12C
Supelco
L-Lysine monohydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
L-Lysine monohydrochloride, BioUltra, ≥99.5% (AT)
Lysine hydrochloride, European Pharmacopoeia (EP) Reference Standard
Metilmetacrilato, European Pharmacopoeia (EP) Reference Standard
Supelco
L-Lysine hydrochloride solution, 100 mM amino acid in 0.1 M HCl, analytical standard
Supelco
L-Lysine monohydrochloride, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland
Supelco
mono-Butyl phthalate, analytical standard
Sigma-Aldrich
Metilmetacrilato, SAJ first grade, ≥99.0%
Sigma-Aldrich
L-Lysine monohydrochloride, SAJ special grade, ≥99.0%